Review
Materials Science, Biomaterials
Zahra Nozhat, Shabnam Heydarzadeh, Mina Shahriari-Khalaji, Shibo Wang, M. Zubair Iqbal, Xiangdong Kong
Summary: Glioblastoma multiforme (GBM) is a difficult-to-treat brain tumor due to the blood-brain tumor barrier (BBTB) and limited available drugs. However, recent research has shown that the use of nanoscale biomaterials can overcome these challenges and improve drug delivery to the tumor site.
BIOMATERIALS SCIENCE
(2023)
Article
Chemistry, Multidisciplinary
Puja Sandbhor, Jayant Goda, Bhabani Mohanty, Pradip Chaudhari, Shilpee Dutt, Rinti Banerjee
Summary: The study suggests that targeted nanovesicles delivered through the intranasal route have the potential to bypass the blood-brain barrier, significantly increase brain drug bioavailability, and achieve better therapeutic outcomes in the treatment of glioblastoma.
Review
Biochemistry & Molecular Biology
Mariceli Baia Leao Barros, Danilo do Rosario Pinheiro, Barbara do Nascimento Borges
Summary: Glioblastoma (GBM) is a highly aggressive tumor originating from neural stem cells of the central nervous system, with mutations in mitochondrial DNA (mtDNA) leading to mitochondrial dysfunction, playing a crucial role in GBM pathogenesis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Nguyen Thi Thanh Ho, Chinmay Satish Rahane, Subrata Pramanik, Pok-Son Kim, Arne Kutzner, Klaus Heese
Summary: This review discusses the significance of the gene pair |-SRGAP2-FAM72-| in the treatment of GBM and other cancers, as well as the potential of neural stem cells in regenerative medicine. It highlights the role of the SRGAP2-Family with sequence similarity 72 (FAM72) master gene in cell renewal and differentiation, emphasizing the importance of monitoring this gene for cancer prevention and treatment.
Article
Pharmacology & Pharmacy
Leonardo Delello Di Filippo, Juliana Hofstatter Azambuja, Jessyca Aparecida Paes Dutra, Marcela Tavares Luiz, Jonatas Lobato Duarte, Luiza Ribeiro Nicoleti, Sara Teresinha Olalla Saad, Marlus Chorilli
Summary: Glioblastoma multiforme (GBM) is the most common primary brain cancer with aggressive development and increasing resistance to drugs like temozolomide (TMZ). Functionalized nanocarriers can serve as an efficient and safe strategy for delivering TMZ, improving its biopharmaceutical properties and potentially repurposing its use in anti-GBM therapy.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
(2021)
Review
Biochemistry & Molecular Biology
Marianna Makowska, Beata Smolarz, Hanna Romanowicz
Summary: Glioblastoma multiforme (GBM) is a common, malignant brain tumor with a poor prognosis. Traditional treatments have limited success due to the tumor's infiltrating growth and resistance. The search for new therapies is crucial.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Pharmacology & Pharmacy
Tanisha Gupta, Rakesh K. Sahoo, Himani Singh, Sumeet Katke, Akash Chaurasiya, Umesh Gupta
Summary: Glioblastoma multiforme (GBM) is a highly malignant brain tumor that poses significant treatment challenges due to the blood brain barrier (BBB) and blood brain tumor barrier (BBTB). This review discusses the etiology of these barriers and explores the potential of lipid-based nanocarriers for effective management of GBM, including liposomes, solid lipid nanocarriers (SLNs), nanostructured lipid carriers (NLCs), lipoplexes, and lipid hybrid carriers.
Review
Oncology
Roxanne Wouters, Sien Bevers, Matteo Riva, Frederik De Smet, An Coosemans
Summary: Glioblastoma remains a highly aggressive brain tumor with limited treatment options, despite the advancements in preclinical immunotherapeutic approaches. The discrepancy between successful animal experiments and clinical trials may be attributed to the inability of current mouse models to fully replicate the complexity and heterogeneity of the disease. Understanding and combining different mouse models may be crucial in capturing the full spectrum of GBM for effective research and drug testing.
Review
Oncology
Patrick A. DeSouza, Xuan Qu, Hao Chen, Bhuvic Patel, Christopher A. Maher, Albert H. Kim
Summary: Developing effective therapies for GBM is challenging due to tumor heterogeneity and therapeutic resistance. Understanding the mechanisms and impact of long noncoding RNAs is crucial for improving management and outcomes in this aggressive brain cancer.
Article
Oncology
Marta Lopes, Joana Vieira de Castro, Marta Pojo, Celine S. Goncalves, Eduarda P. Martins, Barbara Coimbra, Ioannis Sotiropoulos, Nuno Sousa, Ana Joao Rodrigues, Bruno M. Costa
Summary: The association between chronic stress and cancer is still controversial, and its role in brain tumors is unclear. This study investigated the relationship between chronic stress and glioblastoma aggressiveness using mouse models. The results suggested that chronic stress and glucocorticoids do not significantly affect the aggressiveness of glioblastoma in mice.
FRONTIERS IN ONCOLOGY
(2022)
Review
Pharmacology & Pharmacy
Wei Wu, Jessica L. Klockow, Michael Zhang, Famyrah Lafortune, Edwin Chang, Linchun Jin, Yang Wu, Heike E. Daldrup-Link
Summary: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor with highly infiltrative nature and treatment resistance, highlighting the importance of innovative treatment strategies. The standard treatment for GBM is surgical resection followed by chemoradiotherapy, but the robust DNA repair and self-renewing capabilities of GBM cells lead to resistance against current therapies.
PHARMACOLOGICAL RESEARCH
(2021)
Article
Cell Biology
Filippo Birocchi, Melania Cusimano, Federico Rossari, Stefano Beretta, Paola M. Rancoita, Anna Ranghetti, Stefano Colombo, Barbara Costa, Peter Angel, Francesca Sanvito, Marcella Callea, Rossana Norata, Linda Chaabane, Tamara Canu, Antonello Spinelli, Marco Genua, Renato Ostuni, Ivan Merelli, Nadia Coltella, Luigi Naldini
Summary: In this study, the authors engineered hematopoietic stem cells ex vivo to release interferon-alpha (IFN-alpha) or interleukin-12 (IL-12) at the tumor site, and achieved effective and tolerable treatment for glioblastoma multiforme (GBM) by reprogramming the tumor immune microenvironment.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Review
Oncology
Satya Siva Kishan Yalamarty, Nina Filipczak, Xiang Li, Md Abdus Subhan, Farzana Parveen, Janaina Artem Ataide, Bharat Ashok Rajmalani, Vladimir P. Torchilin
Summary: Glioblastoma multiforme (GBM) is a highly aggressive form of brain cancer that is difficult to treat due to its resistance to traditional cancer treatments. The unique biology of GBM cells and the blood-brain barrier contribute to this resistance. However, there are several treatment options available, including surgery, chemoradiotherapy, adjuvant chemotherapy, immunotherapy, targeted therapies, and tumor-treating fields. Ongoing clinical trials aim to improve outcomes for GBM patients.
Article
Clinical Neurology
Emrah Gumusgoz, Sahba Kasiri, Dikran R. Guisso, Jun Wu, Matthew Dear, Brandy Verhalen, Berge A. Minassian
Summary: Adult polyglucosan body disease (APBD) and Lafora disease (LD) are two autosomal recessive neurological disorders caused by gene mutations. Both diseases share a common pathology of abnormal glycogen accumulation. By reducing the expression of glycogen synthase, we were able to decrease the formation of pathological polyglucosan bodies and improve early neuroinflammatory markers of disease. This study provides proof of principle for a lifelong treatment for APBD and LD, and may be applicable to other glycogen storage diseases.
Article
Oncology
Emilie Thivat, Melanie Casile, Juliette Moreau, Ioana Molnar, Sandrine Dufort, Khalide Seddik, Geraldine Le Duc, Olivier De Beaumont, Markus Loeffler, Xavier Durando, Julian Biau
Summary: This study aims to determine the recommended dose of AGuIX as a radiosensitizer in combination with radiotherapy and TMZ, as well as to assess the efficacy of the combination. The study design is a multicenter, randomized, open-label, non-comparative therapeutic trial, expected to recruit 66 patients. Secondary objectives include assessing the pharmacokinetics, distribution of nanoparticles, tolerance of the combination, neurological status, overall survival, response to treatment, and progression-free survival.
Article
Medicine, Research & Experimental
Yuwen Zhu, Yan Guo, Yujia Xue, Anqi Zhou, Ying Chen, Yifei Chen, Xiulian Miao, Fangqiao Lv
Summary: BRG1 plays an important role in HSC-myofibroblast transition and targeting it could be a reasonable strategy for liver fibrosis intervention.
Article
Medicine, Research & Experimental
Liu Ye, Beibei Liu, Jingling Huang, Xiaolin Zhao, Yuan Wang, Yungen Xu, Shuping Wang
Summary: Doublecortin-like kinase 1 (DCLK1) is a significant prooncogenic factor that is strongly associated with the malignant progression and clinical prognosis of various cancers. DCLK1 plays important roles in stem cell marker regulation, tumor cell reprogramming, and immune evasion. However, the exact biological functions of DCLK1, especially the disparities between its alpha- and beta-form transcripts in cancer progression, remain ambiguous.
Article
Medicine, Research & Experimental
Jiahui Yang, Xiaoyu Chen, Tianjing Liu, Yongyan Shi
Summary: This article reviews the role of bile acids in necrotizing enterocolitis (NEC) and their potential therapeutic value. The dysregulation of bile acids is associated with intestinal injury, and inflammatory factors in the liver also play a crucial role in regulating bile acid transport. The bile acid metabolic pathway is important for regulating intestinal microbiota, cell proliferation, and barrier protection.
Review
Medicine, Research & Experimental
Zhenzheng Zhu, Yuemiao Xu, Yuwei Xia, Xinru Jia, Yixin Chen, Yuyue Liu, Leyin Zhang, Hui Chai, Leitao Sun
Summary: Bile acid, as the final product of cholesterol breakdown, plays a complex regulatory and signaling role in human metabolism. Research suggests that it has the potential to enhance metabolism and regulate chronic metabolic diseases through various pathways. The interaction between bile acid and gut microbiota is also of great significance.
Article
Medicine, Research & Experimental
Xin He, Hong-Xu Zhou, Xian Fu, Kai-Di Ni, Ai-Zhi Lin, Ling-Tong Zhang, Hou-Hua Yin, Qing Jiang, Xue Zhou, Yi-Wen Meng, Jun-Yan Liu
Summary: DON exposure causes an increase in deoxycholic acid (DCA), which contributes to intestinal injury. DCA may be a potential therapeutic target for DON enterotoxicity.
Article
Medicine, Research & Experimental
Zhitao Wang, Heng Ma, Abdul Nasir, Sufang Liu, Zhisong Li, Feng Tao, Qian Bai
Summary: This study reveals the involvement of TET1-mediated epigenetic regulation in chronic TMJ pain through trigeminal TNF alpha signaling.
Article
Medicine, Research & Experimental
Lu Yu, Hao Ran, Yaru Lu, Qian Ma, Huan Huang, Weibin Liu
Summary: This study found that the HIF-1 alpha inhibitor BAY 87-2243 can alleviate the symptoms of the Experimental Autoimmune Myasthenia Gravis (EAMG) inflammation model. BAY 87-2243 can restore the balance of CD4(+)T cell subsets, reduce the production of pro-inflammatory cytokines, and act as both an immune imbalance regulator and anti-inflammatory.
Article
Medicine, Research & Experimental
Alex Peralvarez-Marin, Montse Sole, Judith Serrano, Alice Taddeucci, Belen Perez, Clara Penas, Gemma Manich, Marcel Jimenez, Pilar D'Ocon, Francesc Jimenez-Altayo
Summary: This study provides the first evidence that TRPV2 channels may modulate vascular tone by balancing opposing inputs from the endothelium and smooth muscle, leading to net vasodilation. The amplification of TRPV2 channel-induced activity by NO emphasizes the pathophysiological relevance of these findings.
Article
Medicine, Research & Experimental
Amin Ullah, Jing Zhao, Jiakun Li, Rajeev K. Singla, Bairong Shen
Summary: Gastric cancer is the fifth-most prevalent and second-most deadly cancer worldwide. Late onset of symptoms makes early detection important. CXC chemokines play an important role in the pathological process of gastric cancer, but their exact role in diagnosis and prognosis is not fully understood. Inhibiting CXC chemokines shows promise as a targeted therapy.
Article
Medicine, Research & Experimental
Menna S. Zeyada, Salma M. Eraky, Mamdouh M. El-Shishtawy
Summary: The current study demonstrates the prophylactic and antifibrotic effects of Trig against BLM-induced PF by targeting multiple signaling pathways. The combination of Trig and Pirf may be a promising approach to enhance Pirf's anti-fibrotic effect.